Dashboard
Manage Tickers

KNSA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

kiniksa-expects-2025-arcalyst-net-product-revenue-of-670m-675m-compared-to-prior-guidance-of-625m-640m
Kiniksa Expects 2025 Arcalyst Net Product ...
10/28/2025 11:43:22

Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.

kiniksa-pharmaceuticals-q3-2025-eps-023-misses-026-estimate-sales-180855m-beat-167358m-estimate
Kiniksa Pharmaceuticals Q3 2025 EPS $0.23 ...
10/28/2025 11:34:29

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

what-to-expect-from-kiniksa-pharmaceuticalss-earnings
What to Expect from Kiniksa Pharmaceutical...
10/27/2025 19:01:12

5-analysts-have-this-to-say-about-kiniksa-pharmaceuticals
5 Analysts Have This To Say About Kiniksa ...
10/17/2025 19:00:49

citigroup-maintains-buy-on-kiniksa-pharmaceuticals-raises-price-target-to-50
Citigroup Maintains Buy on Kiniksa Pharmac...
10/17/2025 15:23:07

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from ...

kiniksa-pharmaceuticals-announces-fda-grants-orphan-drug-designation-for-kpl-387-for-pericarditis
Kiniksa Pharmaceuticals Announces FDA Gran...
10/17/2025 12:06:38

wedbush-maintains-outperform-on-kiniksa-pharmaceuticals-raises-price-target-to-44
Wedbush Maintains Outperform on Kiniksa Ph...
10/13/2025 13:03:03

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price ta...

what-analysts-are-saying-about-kiniksa-pharmaceuticals-stock
What Analysts Are Saying About Kiniksa Pha...
09/29/2025 18:01:32

4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a div...

td-cowen-initiates-coverage-on-kiniksa-pharmaceuticals-with-buy-rating-announces-price-target-of-60
TD Cowen Initiates Coverage On Kiniksa Pha...
09/29/2025 14:19:16

TD Cowen analyst Nicholas Lorusso initiates coverage on Kiniksa Pharmaceuticals (NASDAQ: KNSA) with a Buy rating and announc...

wells-fargo-maintains-overweight-on-kiniksa-pharmaceuticals-raises-price-target-to-45
Wells Fargo Maintains Overweight on Kiniks...
09/25/2025 13:36:22

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ: KNSA) with a Overweight and raises the pri...

why-commscope-shares-are-trading-higher-by-around-40-here-are-20-stocks-moving-premarket
Why CommScope Shares Are Trading Higher By...
08/04/2025 10:55:34

jefferies-maintains-buy-on-kiniksa-pharmaceuticals-raises-price-target-to-54
Jefferies Maintains Buy on Kiniksa Pharmac...
07/29/2025 21:37:39

Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $45...

kiniksa-pharmaceuticals-arcalyst-2025-expected-net-product-revenue-guidance-increased-to-625m-640m-compared-to-prior-guidance-of-590m-605m
Kiniksa Pharmaceuticals' ARCALYST 2025 Exp...
07/29/2025 11:34:09

kiniksa-pharmaceuticals-q2-2025-eps-023-beats-018-estimate-sales-156797m-beat-145218m-estimate
Kiniksa Pharmaceuticals Q2 2025 EPS $0.23 ...
07/29/2025 11:32:43

Core News & Articles
Earnings Scheduled For July 29, 2025
07/29/2025 08:32:31

earnings-preview-kiniksa-pharmaceuticals
Earnings Preview: Kiniksa Pharmaceuticals
07/28/2025 18:01:57

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
07/25/2025 21:06:49

wells-fargo-maintains-overweight-on-kiniksa-pharmaceuticals-raises-price-target-to-42
Wells Fargo Maintains Overweight on Kiniks...
07/09/2025 13:14:44

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the pric...

kiniksa-pharma-announces-details-for-planned-phase-23-clinical-trial-of-kpl-387-in-recurrent-pericarditis-expected-to-initiate-in-middle-of-2025
Kiniksa Pharma Announces Details For Plann...
06/05/2025 11:07:35

– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascendin...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION